checkAd

Juniper Biologics Announces the Appointment of Raman Singh as Chief Executive

Nachrichtenquelle: PR Newswire (engl.)
15.04.2021, 10:30  |  131   |   |   

Singh to lead Juniper Biologics operations from Singapore and deliver medicines in Oncology, Rare/Orphan Diseases and Gene Therapy

SINGAPORE, April 15, 2021 /PRNewswire/ -- Juniper Biologics, a science-led healthcare company focused on researching, developing & commercialising novel therapies, has announced the appointment of celebrated pharmaceutical executive Raman Singh to the role of Chief Executive.

Juniper Biologics will be focused on researching, developing and commercialising innovative medications in the areas of Oncology, Rare/Orphan Diseases and Gene Therapy. The company is headquartered in Singapore.

Juniper Biologics was founded on a vision to provide the next generation of life-changing treatments for unmet needs focused on specialist therapy areas in which it can make the most difference. The company has the goal of bringing in cutting edge innovation and improving the quality of life of the human race and especially in the wake of the COVID-19 pandemic. Mr Singh's plan is to do this by focusing exclusively on much neglected therapy areas, specific biological targets and unique formulations with strong value proposition.

''The opportunity to lead Juniper Biologics is one I could not pass up. There is a tremendous global need for effective therapies and preventions for Oncology, Rare/Orphan Diseases and Gene Therapy. Success would mean alleviation of a lot of human suffering,'' said Raman Singh, CEO, Juniper Biologics.

Mr Singh brings over 25 years of experience from the pharmaceutical industry, most recently as CEO of Mundipharma for its Pharmaceutical & Consumer Business where he grew the emerging markets operations from USD$45 million to close to USD$1billion in eight years. Under Mr Singh's leadership, Mundipharma signed over 60 in-licensing/acquisition deals across multiple therapy areas, covering pharmaceuticals, over-the-counter medicines and fast- moving consumer products. 

Prior to joining Mundipharma, Mr. Singh served as Vice-President of commercial operations for emerging markets at GSK. In his role, he oversaw all aspects of the brand's commercial operations across its emerging markets. Mr. Singh previously held positions at Abbott as the regional director in Australia and New Zealand, and General Manager for Korea, as well as various sales, marketing and strategy positions at Bayer.

Seite 1 von 2



0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Juniper Biologics Announces the Appointment of Raman Singh as Chief Executive Singh to lead Juniper Biologics operations from Singapore and deliver medicines in Oncology, Rare/Orphan Diseases and Gene Therapy SINGAPORE, April 15, 2021 /PRNewswire/ - Juniper Biologics, a science-led healthcare company focused on researching, …

Nachrichten des Autors

Titel
Titel
Titel